Grifols (GRFS) Fundamentals 2026 — P/E 16.0x, Revenue Analysis | SniperIQ
Grifols (GRFS) is a ES-listed Healthcare company in Drug Manufacturers - General with a market capitalization of $6.6B, trading at $7.81 on the NASDAQ. This SniperIQ fundamentals page covers Grifols's valuation (P/E 16.0x, P/B 1.2x), profitability (net margin 5.6%), revenue (€7.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Grifols's market cap?
Grifols (GRFS) has a market capitalization of approximately $6.6B, trading at $7.81 on the NASDAQ. Market cap moves with the live share price.
What is Grifols's P/E ratio?
Grifols's trailing twelve-month P/E ratio is 16.0x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Grifols?
Grifols runs a net profit margin of 5.6%, a gross margin of 37.7%, and an operating margin of 16.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Grifols generate?
Grifols reported revenue of €7.2B for fiscal year 2025, with net income of €386M and earnings per share (EPS) of 0.57. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Grifols pay a dividend?
Grifols offers a trailing dividend yield of about 0.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Grifols financially healthy?
Grifols carries a debt-to-equity ratio of 1.77x and a current ratio of 2.47x, with a market beta of 1.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Grifols a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Grifols (GRFS) the key facts are: market cap $6.6B, P/E 16.0x, revenue €7.2B, 52-week range 6.96-11.14. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Grifols's full fundamentals live
Get Grifols's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.